糖代谢显像对恶性淋巴瘤临床分期和疗效评价  

Clinical Staging and Therapeutic Effective Evaluation of Glucose Metabolic Imaging in Malignant Lymphoma

作　　者：王荣福[1] 张秀梅[1] 岑溪南[1] 

机构地区：[1]北京大学第一医院核医学科,北京100034

出　　处：《当代医学》2009年第14期28-31,共4页Contemporary Medicine

基　　金：国家重点基础研究发展计划(973计划)资助项目[2006CB705705];国家自然科学基金项目[30670583;30470498;30870729];教育部教育振兴行动计划特殊专项("九八五"工程:II期)资助项目[985-2-056]

摘　　要：目的探讨符合线路SPECT18F-FDG代谢显像在恶性淋巴瘤临床分期和疗效判断的临床应用价值。方法我们对8例非霍奇金病(NHL)病人进行18F-FDG符合线路SPECT显像,用定性和半定量方法进行分析,并进行随访。结果8例病人中首次进行18F-FDG显像2例结果阴性,6例阳性。1例病人化疗后出现FDG摄取阳性(T/B=2.39),病理证实NHL转移,改变了临床分期;3例病人在化疗前后进行两次18F-FDG显像,FDG摄取由阳性转为阴性,治疗有效;2例病人化疗后FDG摄取阴性,疗效稳定。结论本法对恶性淋巴瘤的分期和疗效判断不失为一种有用的检测手段。Objective To investigate the value and its clinical application for staging and evaluating the therapeutic effectiveness of lym- phoma using ^18F-FDG SPECT with coincidence detection metabolic imaging. Methods Eight patients underwent ^18F-FDG metabolic imaging. Analysis was made in qualitative and semi-quantitative ways. Rosults Among them Two patients were negative while Six patients were positive. One patient showed positive（T/B = 2. 39） after chemotherapy, pathologically proving to be metastasis of NHL, which led to change clinical staging; Three patient had ^18F- FDG imaging before and after chemotherapy, the ^18F-FDG imaging became negative after chemotherapy which verified the effectiveness of the therapy; Still One patient was negative after chemotherapy which showed that the effectiveness was steady. Conclusion ^18F-FDG imaging appears to be very useful for stag ing and evaluating the therapeutic effectiveness of lymphoma.

关 键 词：^18F^FDG 代谢显像 淋巴瘤 分期 治疗 

分 类 号：R733.1[医药卫生—肿瘤]